About Variantyx
Variantyx is a company based in Boston (United States) founded in 2014 by Haim Neerman and Tomer Jackman.. Variantyx has raised $110.5 million across 6 funding rounds from investors including IBM, Kreos Capital and Bosch Ventures. The company has 122 employees as of December 31, 2022. Variantyx offers products and services including Genomic Unity® 2.0, Exome Plus Analysis, Exome Analysis, and Comprehensive Hereditary Cancer Analysis. Variantyx operates in a competitive market with competitors including Natera, ArcherDX, ImaginAb, Lantern Pharma and RareCyte, among others.
- Headquarter Boston, United States
- Employees 122 as on 31 Dec, 2022
- Founders Haim Neerman, Tomer Jackman
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Variantyx, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$110.5 M (USD)
in 6 rounds
-
Latest Funding Round
$36 M (USD), Series C
Apr 26, 2024
-
Investors
IBM
& 9 more
-
Employee Count
122
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Variantyx
Variantyx offers a comprehensive portfolio of products and services, including Genomic Unity® 2.0, Exome Plus Analysis, Exome Analysis, and Comprehensive Hereditary Cancer Analysis. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Comprehensive analysis for genetic disorders using whole genome sequencing
Targeted genetic testing for specific disorders
In-depth examination of exome for diagnostic purposes
Genetic evaluation for hereditary cancer risks
Unlock access to complete
Unlock access to complete
Funding Insights of Variantyx
Variantyx has successfully raised a total of $110.5M across 6 strategic funding rounds. The most recent funding activity was a Series C round of $36 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Series C — $36.0M
-
First Round
First Round
(06 Jun 2019)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2024 | Amount | Series C - Variantyx | Valuation |
investors |
|
| Oct, 2023 | Amount | Series C - Variantyx | Valuation |
investors |
|
| Oct, 2022 | Amount | Debt – Conventional - Variantyx | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Variantyx
Variantyx has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include IBM, Kreos Capital and Bosch Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are made in innovative technology startups.
|
Founded Year | Domain | Location | |
|
Venture capital investments in tech and healthtech sectors through dedicated funds.
|
Founded Year | Domain | Location | |
|
Early-stage tech startups are funded by the venture capital firm.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Variantyx
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Variantyx
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Variantyx Comparisons
Competitors of Variantyx
Variantyx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Natera, ArcherDX, ImaginAb, Lantern Pharma and RareCyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| domain | founded_year | HQ Location |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| domain | founded_year | HQ Location |
ImaginAb is focused on developing advanced immuno-oncology imaging technologies.
|
|
| domain | founded_year | HQ Location |
Drug and companion diagnostics for multi-drug resistant cancers are developed.
|
|
| domain | founded_year | HQ Location |
Developer of technologies for the analysis of rare and single cells in the blood
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Variantyx
Frequently Asked Questions about Variantyx
When was Variantyx founded?
Variantyx was founded in 2014 and raised its 1st funding round 5 years after it was founded.
Where is Variantyx located?
Variantyx is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Who is the current CEO of Variantyx?
Haim Neerman is the current CEO of Variantyx. They have also founded this company.
Is Variantyx a funded company?
Variantyx is a funded company, having raised a total of $110.5M across 6 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $21M, raised on Jun 06, 2019.
How many employees does Variantyx have?
As of Dec 31, 2022, the latest employee count at Variantyx is 122.
What does Variantyx do?
Variantyx was founded in 2014 and is headquartered in Boston, United States. An integrated platform is provided for the analysis, interpretation, and reporting of next-generation sequencing data in the genomics sector. Whole-genome sequencing data is utilized through partnerships with sequencing providers, followed by automated processing and clinical report generation. Comprehensive molecular diagnostics are delivered for various disease areas in healthcare settings.
Who are the top competitors of Variantyx?
Variantyx's top competitors include Natera, ImaginAb and Lantern Pharma.
What products or services does Variantyx offer?
Variantyx offers Genomic Unity® 2.0, Exome Plus Analysis, Exome Analysis, and Comprehensive Hereditary Cancer Analysis.
Who are Variantyx's investors?
Variantyx has 10 investors. Key investors include IBM, Kreos Capital, Bosch Ventures, Pitango, and New Era Capital Partners.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.